



## WHOLE EXOME SEQUENCING (WES) REQUISITION

Patient Last Name \_\_\_\_\_ Patient First Name \_\_\_\_\_ MI \_\_\_\_\_ Date of Birth (MM / DD / YYYY) \_\_\_\_\_ Genetic Sex \_\_\_\_\_

### INSTRUCTIONS FOR ORDERING

Any combination of Chromosomal Microarray Analysis (CMA), mtDNA Analysis, or Global MAPS® can be ordered along with a WES test, however the turnaround time for results will differ from exome sequencing.

### TRIO WES TEST OPTIONS

- |  |   |   |
|--|---|---|
| <input type="checkbox"/> 1600 Trio Whole Exome Sequencing                                      | <b>CORRESPONDING PARENTAL TESTS</b><br>(Both Biological Parents Are Required) | <input type="checkbox"/> 1550 Parental WES - Maternal   |
| <input type="checkbox"/> 1532 Trio Whole Exome Sequencing + Comprehensive mtDNA Analysis       |   | <input type="checkbox"/> 1550 Parental WES - Paternal   |
| <input type="checkbox"/> 1722 Rapid Trio Whole Exome Sequencing                                |   | <input type="checkbox"/> 1602 WES - Additional Affected Sibling   |
| <input type="checkbox"/> 1533 Rapid Trio Whole Exome Sequencing + Comprehensive mtDNA Analysis |   | <b>NOTE:</b> Please use separate <i>Additional Affected Sibling</i> for Trio requisition for additional family members. |

### DUO WES TEST OPTIONS

- |  |  |   |
|--|--|---|
| <input type="checkbox"/> 1603 Duo Whole Exome Sequencing       | <b>CORRESPONDING PARENTAL TESTS</b> (One Parent Is Required) | <b>NOTE:</b> Please use separate <i>Additional Affected Sibling</i> for Trio requisition for additional family members. |
| <input type="checkbox"/> 1723 Rapid Duo Whole Exome Sequencing |  |   |

### PROBAND WES TEST OPTIONS

- |  |   |  |
|--|---|--|
| <input type="checkbox"/> 1500 Proband Whole Exome Sequencing   | <input type="checkbox"/> 1531 Proband Whole Exome Sequencing + Comprehensive mtDNA Analysis | <b>CORRESPONDING PARENTAL TESTS</b><br><input type="checkbox"/> 6997 Optional Parental Control |
| <input type="checkbox"/> 1530 Proband Whole Exome Sequencing + Chromosomal Microarray Analysis (CMA) (Comprehensive) |   |  |

### GLOBAL MAPS® TESTS

- 4900 Global Metabolomic Assisted Pathway Screen - Plasma from EDTA  
Was plasma extracted from EDTA?     Yes     No
- 4901 Global Metabolomic Assisted Pathway Screen - Urine

### ADD-ON TESTS

- 8665 Chromosomal Microarray Analysis (CMA)-HR+SNP Screen (Comprehensive)
- 2055 Comprehensive mtDNA analysis by NGS
- 9815 Exome Raw Data Release

### ADDITIONAL REPORTING OPTIONS

If a box is not checked the lab will default to No / Not Report.

- Opt-In for incidental findings     Opt-In for potentially clinically significant findings in genes with no known disease association (for Trio WES only)

### PROBAND SAMPLE(S)

Please refer to [www.baylorgenetics.com](http://www.baylorgenetics.com) for full sample requirements.

- |   |  |                                       |  |                             |
|---|--|---------------------------------------|--|-----------------------------|
| <input type="radio"/> Whole Blood in EDTA | <input type="radio"/> Cultured Skin Fibroblast | <input type="radio"/> Skeletal Muscle | <input type="radio"/> Plasma from EDTA | <input type="radio"/> Urine |
| <input type="radio"/> Buccal Swab         | <input type="radio"/> Extracted DNA from _____ | <input type="radio"/> Liver           | _____ / _____ / _____                  |                             |
| <input type="radio"/> Saliva              |  | <input type="radio"/> Tissue          | Date of Collection (MM / DD / YYYY)    |                             |
| <input type="radio"/> Cord Blood          |  |                                       |  |                             |

**NOTE:** Extracted DNA/RNA will only be accepted if the isolation of nucleic acids for clinical testing occurs in a CLIA-certified laboratory or a laboratory meeting equivalent requirements as determined by the CAP and/or the CMS.

### BIOLOGICAL PARENTS INFORMATION

BIOLOGICAL PARENTS SAMPLES ARE REQUIRED FOR TRIO WES; Other family members cannot be substituted for either parent. Be sure to label parental samples with full name and date of birth - DO NOT LABEL WITH CHILD'S NAME. Must sign parental testing authorization on consent.

#### MATERNAL INFORMATION

- Asymptomatic     Symptomatic (Attach summary of findings)

Maternal Last Name \_\_\_\_\_ Maternal First Name \_\_\_\_\_ MI \_\_\_\_\_

Maternal Date of Birth (MM / DD / YYYY) \_\_\_\_\_ / \_\_\_\_\_ / \_\_\_\_\_    Sample Type:  
 Blood in EDTA (preferred)  
 Buccal Swab  
 Saliva

Date of Collection (MM / DD / YYYY) \_\_\_\_\_ / \_\_\_\_\_ / \_\_\_\_\_

#### PATERNAL INFORMATION

- Asymptomatic     Symptomatic (Attach summary of findings)

Paternal Last Name \_\_\_\_\_ Paternal First Name \_\_\_\_\_ MI \_\_\_\_\_

Paternal Date of Birth (MM / DD / YYYY) \_\_\_\_\_ / \_\_\_\_\_ / \_\_\_\_\_    Sample Type:  
 Blood in EDTA (preferred)  
 Buccal Swab  
 Saliva

Date of Collection (MM / DD / YYYY) \_\_\_\_\_ / \_\_\_\_\_ / \_\_\_\_\_

## WHOLE EXOME SEQUENCING (WES) REQUISITION

Patient Last Name \_\_\_\_\_ Patient First Name \_\_\_\_\_ MI \_\_\_\_\_ Date of Birth (MM / DD / YYYY) \_\_\_\_\_ Genetic Sex \_\_\_\_\_

### ITEM CHECKLIST FOR TESTING

- |  |  |   |
|--|--|---|
| <input type="checkbox"/> Proband Sample (Required)               | <input type="checkbox"/> Signed WES Consent Form | <input type="checkbox"/> Indication for Study |
| <input type="checkbox"/> Maternal Sample (Required for Trio WES) | <input type="checkbox"/> Clinical Note/Summary   | <input type="checkbox"/> Pedigree (Optional)  |
| <input type="checkbox"/> Paternal Sample (Required for Trio WES) | <input type="checkbox"/> Requisition             |   |

### INDICATION FOR TESTING (REQUIRED)

Please provide the following clinical information regarding the patient to be tested. Please also submit a clinic note and pedigree, if available. Phenotypes listed are in HPO terms with the corresponding HPO number (<http://human-phenotype-ontology.github.io/>). This information is needed to facilitate interpretation of whole exome sequencing results. If the laboratory requires additional information, please indicate the health care provider to be contacted:

#### PRE/PERINATAL HISTORY

- 0001622 Prematurity - GA at birth \_\_\_\_\_
- 0001511 Intrauterine Growth Restrictions
- 0001562 Oligohydramnios
- 0001561 Polyhydramnios
- 0000476 Cystic Hygroma
- 0000776 Congenital Diaphragmatic Hernia
- 0001508 Failure to Thrive
- 0001539 Omphalocele
- 0002084 Encephalocele
- 0010880 Increased Nuchal Translucency
- \_\_\_\_\_

#### EYE DEFECTS & VISION

- 0000505 Visual Impairment
- 0000618 Blindness
- 0000589 Coloboma
- 0000526 Aniridia
- 0000528 Anophthalmia
- 0000568 Microphthalmia
- 0000508 Ptosis
- 0000486 Strabismus
- 0000519 Cataract Congenital Bilateral
- \_\_\_\_\_
- \_\_\_\_\_

#### MOTOR/COGNITIVE DEVELOPMENT

- 0000750 Delayed Speech & Language Development
- 0001270 Delayed Motor Milestones
- 0002376 Developmental Regression
- Intellectual Disability
  - 0001256 Mild
  - 0002342 Moderate
  - 0010864 Severe
- 0000729 Autistic Spectrum Disorder
- \_\_\_\_\_
- \_\_\_\_\_

#### STRUCTURAL BRAIN ABNORMALITIES

- 0001360 Holoprosencephaly
- 0001339 Lissencephaly
- 0002084 Encephalocele
- 0000238 Hydrocephalus
- 0002119 Ventriculomegaly
- 0001273 Abnormality of Corpus Callosum
- 0002539 Cortical Dysplasia
- 0012444 Brain Atrophy
- 0002352 Leukoencephalopathy
- 0002269 Abnormality of Neuronal Migration
- 0002126 Polymicrogyria
- 0001302 Pachgyria
- 0002500 Abnormality of Cerebral White Matter
- 0007266 Cerebral Dysmyelination
- 0006808 Cerebral Hypomyelination
- 0002134 Abnormality of the Basal Ganglia
- 0002363 Abnormality of the Brainstem
- 0007360 Aplasia/Hypoplasia of the Cerebellum
- 0006817 Aplasia/Hypoplasia of the Cerebellar Vermis
- \_\_\_\_\_

#### NEUROLOGICAL

- 0001284 Areflexia
- 0200134 Epileptic Encephalopathy
- 0001250 Seizures
  - 0002373 Febrile Seizures
  - 0012469 Infantile Spasms
  - 0002123 Generalized Myoclonic Seizures
  - 0002069 Generalized Tonic-clonic Seizures
  - 0010818 Generalized Tonic Seizures
  - 0010819 Atonic Seizures
  - 0002121 Absence Seizures
  - 0011169 Generalized Clonic Seizures
  - 0001251 Ataxia
  - 0001332 Dystonia
  - 0002072 Chorea
  - 0001257 Spasticity
  - 0009830 Neuropathy
- \_\_\_\_\_
- \_\_\_\_\_

#### CRANIOFACIAL

- 0000256 Macrocephaly
- 0000252 Microcephaly
- 0001363 Craniosynostosis
- 0000204 Cleft Upper Lip
- 0000175 Cleft Palate
- 0000316 Hypertelorism
- 0000601 Hypotelorism
- 0008050 Abnormality of the Palpebral Fissures
- 0000286 Epicanthal Folds
- 0000288 Abnormality of the Philtrum
- 0010938 Abnormality of the External Nose
- \_\_\_\_\_
- \_\_\_\_\_

Indications continued on next page



## WHOLE EXOME SEQUENCING (WES) REQUISITION

Patient Last Name \_\_\_\_\_

Patient First Name \_\_\_\_\_

MI \_\_\_\_\_

Date of Birth (MM / DD / YYYY) \_\_\_\_\_ / \_\_\_\_\_ / \_\_\_\_\_

Genetic Sex \_\_\_\_\_

### INDICATION FOR TESTING (REQUIRED) - CONTINUED

#### HAIR & SKIN

- 0000957 Cafe-Au-Lait Spots
- 0001034 Hypermelanotic Macule
- 0001010 Hypopigmentation of the Skin
- 0008066 Abnormal Blistering of the Skin
- 0008064 Ichthyosis
- 0000988 Skin Rash
- 0001581 Recurrent Skin Infections
- 0005306 Capillary Hemangiomas
- 0001597 Abnormality of the Nail
- 0004554 Generalized Hypertrichosis
- 0001596 Alopecia
- 0002208 Coarse Hair
- 0002299 Brittle Hair
- \_\_\_\_\_
- \_\_\_\_\_

#### CARDIAC

- 0001631 Atria Septal Defect
- 0001629 Ventricular Septal Defect
- 0001655 Patent Foramen Ovale
- 0001713 Abnormality of Cardiac Ventricle
- 0001636 Tetralogy of Fallot
- 0001680 Coarctation of Aorta
- 0001647 Bicuspid Aortic Valve
- 0002616 Aortic Root Dilatation
- 0001638 Cardiomyopathy
- 0011675 Arrhythmia
- \_\_\_\_\_
- \_\_\_\_\_

#### GENITOURINARY

- 0000113 Polycystic Kidney Dysplasia
- 0000107 Renal Cyst
- 0008738 Partially Duplicated Kidney
- 0000104 Renal Agenesis
- 0000085 Horseshoe Kidney
- 0000069 Abnormality of the Ureter
- 0000795 Abnormality of the Urethra
- 0000047 Hypospadias
- 0000028 Cryptorchidism
- 0000035 Abnormality of the Testis
- 0000062 Ambiguous Genitalia
- \_\_\_\_\_
- \_\_\_\_\_

#### RESPIRATORY

- 0002093 Respiratory Insufficiency
- 0002878 Respiratory Failure
- 0002104 Apnea
- 0002791 Hypoventilation
- 0002883 Hyperventilation
- 0002788 Recurrent Upper Respiratory Tract Infections
- \_\_\_\_\_
- \_\_\_\_\_

#### METABOLIC

- 0001946 Ketosis
- 0003074 Hyperglycemia
- 0001943 Hypoglycemia
- 0001941 Acidosis
- 0003128 Lactic Acidosis
- 0003215 Dicarboxylic Aciduria
- 0002490 Increased CSF lactate
- 0001992 Organic Aciduria
- 0030085 Abnormal CSF Lactate Level
- 00003542 Increased Serum Pyruvate
- 0003535 3-Methylglutaconic aciduria
- 0001942 Metabolic acidosis
- 0100493 Hypoammonemia
- 0001987 Hyperammonemia
- 0004923 Hyperphenylalaninemia
- 0003234 Decreased Plasma Carnitine
- 0003236 Elevated Serum Creatine Phosphokinase
- Abnormal Newborn Screen
- Unusual Color/Odor
- \_\_\_\_\_
- \_\_\_\_\_

#### MUSCULOSKELETAL

- 0011398 Hypotonia
- 0001276 Hypertonia
- 0000098 Tall Stature
- 0004322 Short Stature
- 0001382 Joint Hypermobility
- 0001371 Flexion Contracture
- 0002804 Arthrogryposis Multiplex Congenita
- 0001161 Hand Polydactyly
- 0001829 Foot Polydactyly
- 0006101 Finger Syndactyly
- 0001770 Toe Syndactyly
- 0100490 Camptodactyly of Finger
- 0012165 Oligodactyly
- 0001762 Talipes Equinovarus
- 0002757 Recurrent Fractures
- 0002650 Scoliosis
- 0002808 Kyphosis
- 0003307 Hyperlordosis
- 0001528 Hemihypertrophy
- 0001513 Obesity
- 0001548 Overgrowth
- 0002652 Skeletal Dysplasia
- \_\_\_\_\_
- \_\_\_\_\_

#### GASTROINTESTINAL

- 0002021 Pyloric Stenosis
- 0002575 Tracheoesophageal Fistula
- 0002032 Esophageal Atresia
- 0002020 Gastroesophageal Reflux
- 0001733 Pancreatitis
- 0002014 Diarrhea
- 0002019 Constipation
- 0002037 Inflammatory Bowel Disease
- 0004389 Intestinal Pseudo-Obstruction
- 0001399 Hepatic Failure
- 0002572 Episodic Vomiting
- 0001744 Splenomegaly
- 0002240 Hepatomegaly
- 0001508 Postnatal Failure to Thrive
- 0002578 Gastroparesis
- \_\_\_\_\_
- \_\_\_\_\_

Indications continued on next page

## WHOLE EXOME SEQUENCING (WES) REQUISITION

Patient Last Name \_\_\_\_\_ Patient First Name \_\_\_\_\_ MI \_\_\_\_\_ Date of Birth (MM / DD / YYYY) \_\_\_\_\_ Genetic Sex \_\_\_\_\_

### INDICATION FOR TESTING (REQUIRED) - CONTINUED

**ENDOCRINE** ..... **HEMATOLOGY** ..... **OTHER** .....

- 0000819 Diabetes Mellitus
- 0000873 Diabetes Insipidus
- 0000821 Hypothyroidism
- 0000829 Hypoparathyroidism
- 0000834 Abnormality of the Adrenal Glands
- 0001738 Exocrine Pancreatic Insufficiency
- 0002721 Immunodeficiency
- \_\_\_\_\_
- \_\_\_\_\_

- 0001875 Neutropenia
  - 0005549 Congenital
  - Chronic
  - Cyclic
- 0001873 Thrombocytopenia
- 0040185 Macrothrombocytopenia
- 0005537 Decreased Mean Platelet Volume
- 0005518 Erythrocyte Macrocytosis
- 0004444 Spherocytosis
- 0012410 Pure Red Cell Aplasia
  - Aplastic
  - Hypoplastic
- 0001903 Anemia
- 0005528 Bone Marrow Hypocellularity
- \_\_\_\_\_
- \_\_\_\_\_

- Organomegaly
- Chronic Infections
- 0004311 Abnormality of Macrophages
- 0001954 Episodic Fever
- 0004313 Hypogammaglobulinemia
- 0010701 Abnormal Immunoglobulins
- 0002721 Immunodeficiency
- 0012088 Abnormal urinary odor
- 0012537 Food intolerance
- 0008067 Abnormally lax or hyperextensible skin
- Abnormal Movements
- Family History of Similar Disorder
- 0001254 Lethargy
- 0002415 Leukodystrophy
- \_\_\_\_\_
- \_\_\_\_\_

**EAR DEFECTS & HEARING** .....

- 0000407 Sensorineural Hearing Impairment
  - 0008619 Bilateral
- 0000405 Conductive Hearing Impairment
- 0000410 Mixed Hearing Impairment
- 0004467 Preauricular Pit
- 0000384 Preauricular Skin Tag
- 0000369 Low-set Ears
- 000037 Abnormality of the Pinna
- \_\_\_\_\_
- \_\_\_\_\_

**CANCER** .....

- Type of Cancer \_\_\_\_\_
- Age of Diagnosis \_\_\_\_\_
- Family History of Cancer and Affected Relatives \_\_\_\_\_
- \_\_\_\_\_
- \_\_\_\_\_

**GENES OF INTEREST** .....

\_\_\_\_\_  
 \_\_\_\_\_  
 \_\_\_\_\_  
 \_\_\_\_\_

### ADDITIONAL CLINICAL INFORMATION

### DIFFERENTIAL DIAGNOSIS

Consent on next page



## WHOLE EXOME SEQUENCING (WES) CONSENT

\_\_\_\_\_  
Patient Last Name

\_\_\_\_\_  
Patient First Name

\_\_\_\_\_  
MI

\_\_\_\_\_/\_\_\_\_\_/\_\_\_\_\_  
Date of Birth (MM / DD / YYYY)

\_\_\_\_\_  
Genetic Sex

### INFORMATION AND CONSENT FOR TESTING

#### DESCRIPTION OF WHOLE EXOME SEQUENCING (WES) TEST

The Whole Exome Sequencing (WES) test identifies changes, called variants, in a person's DNA that cause genetic disorders or medical conditions. The WES test provides a comprehensive analysis of the exome, which is the part of the human genome that helps the body make important proteins. The WES test will analyze the important regions of thousands of genes at the same time. Based on the symptoms that are known, genes with changes associated with these symptoms will be reported. WES results are very accurate, but no test is perfect. There is a small chance that DNA changes may not be detected due to limitations of technology or information known about the genes being tested. Results are based on the information available at the time of the testing and may change in the future as medical knowledge changes. It is possible that even if WES identifies the underlying genetic cause for a disorder in a family this information may not help in predicting medical outcomes or change medical management or treatment of disease. WES testing may also identify information about genes and diseases that have clear and immediate medical significance to your health or the health of your family members, even if that information is not related to currently known symptoms. You may consider discussing the significance of your results with your healthcare provider or genetic counselor.

### TEST RESULTS

You may receive any of the following types of results:

- **Positive:** Positive results mean there are one or more changes in the genetic material related to your medical issues.
- **Negative:** Negative results mean no relevant genetic change could be detected using WES. Genetic testing, while highly accurate, might not detect a change present in the genes tested. This can be due to limitations of the information available about the genes being tested, or limitations of the testing technology. In addition, WES does not test all of the genes in the genome due to technical limitations.
- **Results of Unclear Significance:** WES can detect change(s) in DNA that do not have clear meaning. These changes are also referred to as variants of uncertain significance (VUS). Additional studies may be indicated if a VUS is identified in a gene that may be associated with your medical condition.

### INCIDENTAL FINDINGS

This test may also find changes in genes that cause symptoms or diseases not related to the reason for having the test. These are called Secondary Findings and are associated with clear and immediate medical significance to your health or the health of your family members.

#### Category I: ACMG Secondary Findings

The American College of Medical Genetics (ACMG) has published guidelines for the reporting of these types of medically actionable or secondary findings (PMID: 34012068). These guidelines include a list of genes, which are updated occasionally, that are considered medically actionable and indicate laboratories should report pathogenic (disease-causing) findings in these genes. In accordance with an update to this policy statement (PMID: 25356965), you may choose to opt-in to receive this information.

#### Category II: Other Incidental Findings

Medically actionable variants are changes found in genes known to be associated with disease but not associated with your current symptoms or clinical presentation. These variants are reported as they may cause severe, early-onset disease or may have implications for treatment and prognosis. You may choose to opt-in to receive this information.

### ADDITIONAL REPORTING CONSIDERATIONS

The interpretation of the test results is based on information available at the time of testing. As medical knowledge advances, our interpretation of these results may change in the future. We expect to find hundreds of changes when testing a person's DNA, and most of these changes do not relate to disease and therefore will not be reported. The raw sequence data generated by WES is available for request once a WES report has been issued. Please see our website for further information.

The report will NOT include findings in genes causing adult-onset neurodegenerative syndromes for which there is presently no prevention or cure. If the reason for testing includes features that clearly indicate such a disorder, we recommend pursuing targeted testing based on specific symptoms and not WES testing. However, if the reason for testing includes a clinical presentation that could include such a disorder, then results may be reported in the proband (patient) and the parents for genes that have an allelic association with dementia or is a component of the phenotype.

**Additional considerations for Trio WES (test codes 1600, 1722, 1532, 1533):** As part of the Trio WES test, blood samples from the biological parents of the proband are required. Trio WES will be performed on the proband and parental samples at the same time and the sequence data will be analyzed in the context of the family relationships. The parental data will be used to help interpret the proband's data. We will report changes in genes that are present in the affected individual, but not in the asymptomatic parents. This category of results caused by new (de novo) findings may be significant in determining the cause of the medical condition. Thus, this category of changes will be reported for genes with a known current association with disease. We will also report changes in genes where each parent has one change and the affected individual has inherited both changes. Custom Family Sequence Analysis (test code 1580) is available for other family members at an additional charge. Free testing for variants of unknown significance is available with prior approval. A separate parental report will be issued regarding ACMG secondary findings.

continue on next page

**WHOLE EXOME SEQUENCING (WES) CONSENT**

\_\_\_\_\_  
Patient Last Name                      Patient First Name                      MI                      /                      /                      \_\_\_\_\_  
Date of Birth (MM / DD / YYYY)                      Genetic Sex

**ADDITIONAL REPORTING CONSIDERATIONS**

**Additional considerations for Duo WES (test codes 1603, 1623):** As part of the Duo WES test, a sample from one biological parent is required. Duo WES will be performed on the proband and parental sample at the same time and the sequence data will be analyzed in the context of the family relationships. The parental data will be used to help interpret the proband's data. Custom Family Sequence Analysis (test code 1580) is available for family members at an additional charge. Free testing for variants of unknown significance is available with prior approval. A separate parental report will be issued regarding secondary findings.

**Additional reporting for Proband WES (test codes 1500, 1530,1531):** Biological parental samples may help facilitate interpretation of Proband WES results. After the proband report is issued, the parental samples received will be tested by Whole Exome Sequencing (test code 1551) for the entire exome, or will be tested by targeted methods such as Sanger sequencing (test code 1580) for changes in genes that are highly likely to be causative of disease in the affected individual to confirm mode of inheritance, de novo status, etc. as determined necessary by the laboratory. Testing of parental status will ONLY be initiated if there is a variant identified in the proband. For targeted testing on the variants detected in the proband's exome data, test code 1580 is available for all family members. Free testing for variants of unknown significance in the immediate family members is available if approved by Baylor Genetics.

**Your physician may order additional tests along with WES. Further test code specific information is as follows:**

**Test codes 1531, 1532 and 1533:** In addition to WES analysis as detailed above, this order will also include a separate analysis of the mitochondrial DNA.

**Test code 2055:** This order is an analysis of the Mitochondrial DNA (mtDNA). This will be reported separately from the WES results with a turnaround time of 14-28 days. If a change in the mtDNA is identified, the report will indicate recommendations for familial follow-up. Baylor Genetics will NOT automatically initiate testing on the maternal sample. If this is desired, please contact client services for assistance.

**Test code 1530:** This order will also include a separate Chromosomal Microarray Analysis for the detection of deletions and duplications (missing or extra regions of DNA) plus a screen for uniparental disomy (UPD) and absence of heterozygosity (AOH), which are changes that can be associated with an increased risk for certain genetic conditions.

**Test code 8665:** The result of this Chromosomal Microarray Analysis (including copy number changes and UPD/AOH detection) will be reported separately from the WES results with a turnaround time of 14 days. If a copy number change is identified, the report will indicate recommendations for familial follow-up. Baylor Genetics will NOT automatically initiate testing on the parental sample(s). If this is desired, please contact client services for assistance.

**Test codes 4900 and 4901:** This is a large scale, semi-quantitative screening test that looks at changes related to biochemical and metabolic conditions. This is a screening tool for individuals who have symptoms that are not clearly associated with a known disease or as supportive evidence in individuals with results of unclear significance in genes related to biochemical and metabolic conditions. It is not intended to replace current diagnostic testing for specific conditions, nor is it intended for monitoring therapy of a diagnosed condition. Any abnormalities detected using Global MAPS® should be confirmed by diagnostic biochemical or molecular diagnostic testing.

This is the consent for WES testing and does not need to be completed if only Chromosomal Microarray Analysis, Mitochondrial DNA Analysis, or Global MAPS® is ordered. Please visit the Baylor Genetics website for further information about these tests and their associated consent forms.

**CONSIDERATIONS AND LIMITATIONS** .....

1. It is possible that you could have a change in a gene included in the WES test, but the WES test was unable to detect the change. Therefore, it is possible that you may be affected with one of the conditions tested by WES, but that the test did not detect the change associated with this condition.
2. The WES test does not analyze all of the genes in the human genome. There are some genes that cannot be included in the test due to technical limitations.
3. Results may be unclear or indicate the need for further testing on other family members
4. It is possible that additional information may come to light during these studies regarding family relationships. For example, data may suggest that family relationships are not as reported, such as non-paternity (the father of the individual is not the biological father) or consanguinity (reproductive partners are blood relatives). Since the accurate assignment of family relationships is critical to the analysis of WES, we may perform a separate genetic test to confirm that the samples that were submitted from the parents were correctly identified. If a discrepancy is identified, we will proceed with testing for the individual(s) who are correctly identified.
5. If you sign the consent form, but you no longer wish to have your samples tested by WES, you can contact your doctor to cancel the test. If testing is complete, but you have not received your results yet, you can inform your doctor that you no longer wish to receive the results. However, if you withdraw consent for testing after 5:00 p.m. CST the next business day following sample receipt by the laboratory, you will be charged for the full cost of the test.
6. Changes identified by WES may be submitted to public databases, such as ClinVar, to contribute knowledge to the medical profession. Usually limited clinical information is also required for the submission. However, it is unlikely that contents of the database submissions will include any information that will identify you personally.
7. Because many different genes and conditions are being analyzed, there is a risk that you will learn genetic information about yourself or your family that is not directly related to the reason for ordering the WES. This information might relate to diseases with symptoms that may develop in the future in yourself or other family members as well as conditions that have no current treatment.
8. It is possible that even if WES identifies the underlying genetic cause for the disorder in your family, this information may not help in predicting prognosis or change management or treatment of disease.

## WHOLE EXOME SEQUENCING (WES) CONSENT

\_\_\_\_\_  
 Patient Last Name                      Patient First Name                      MI                      Date of Birth (MM / DD / YYYY)                      Genetic Sex

### PATIENT CONFIDENTIALITY AND SPECIMEN RETENTION

Results will only be released to a licensed healthcare provider, to those allowed access to test results by law, and to those authorized in writing.

In rare cases, persons with genetic diagnoses have experienced problems with insurance coverage and employment. The U.S. Federal Government has enacted several laws that prohibit discrimination based on genetic test results by health insurance companies and employers. In addition, these laws prohibit unauthorized disclosure of this information. For more information, you can visit [www.genome.gov/10002077](http://www.genome.gov/10002077).

Samples will be retained in the laboratory in accordance with the laboratory retention policy.

After testing is complete, the de-identified submitted specimen may be used for test development and improvement, internal validation, quality assurance, and training purposes. DNA specimens are not returned to individuals or to referring healthcare providers unless specific prior arrangements have been made.

Samples from residents of New York State will not be included in the de-identified research studies described in this authorization and will not be retained for more than 60 days after the sample was collected, unless specifically authorized by your selection. No tests other than those authorized shall be performed on the biological sample.

Information including results, indications for testing, and clinical status obtained from the hereditary cancer gene testing may be shared with healthcare providers, scientists, and healthcare databases or used in scientific publications or presentations, but the personal identifying information of all persons studied will not be revealed in such data sharing or publications/presentations.

### PATIENT REPORTING OPTIONS AND AUTHORIZATION

Please read the statements below carefully and check the appropriate box and initial. Due to the nature of the methodology of this testing we are unable to guarantee that all pathogenic (disease-causing) variants in each option will be detected by the WES testing. Please refer to the Baylor Genetics website for up-to-date information on the detectable range of the WES test.

DNA Prep (test code 6997): At the discretion of Baylor Genetics, select parental analyses may be performed and reported under Sequential Trio Whole Exome Sequencing (test code 1551) or Custom Family Sequence Analysis (test code 1580) per the additional reporting for Proband WES protocol in the consent below.

*For Options 1 & 2: If neither box is checked, or if the form is not signed, consent is interpreted as "NO."*

INITIAL      1. SECONDARY FINDINGS

Pathogenic and likely pathogenic variants in genes included in the ACMG policy statement regarding recommendations for reporting of secondary findings will be reported as medically actionable on the WES report.

\_\_\_\_\_  
 **YES**      Please report pathogenic and likely pathogenic variants in genes determined to be medically actionable by the ACMG policy statement.

\_\_\_\_\_  
 **NO**      Please do NOT report pathogenic or likely pathogenic variants in genes included in the ACMG policy statement.

INITIAL      2. OPTION TO ALLOW RELEASE OF UPDATED RESULTS

If a possible diagnosis can be made with this information we would like to issue an updated report to the physician who ordered your WES test. This review does NOT include a complete review of all of your data.

\_\_\_\_\_  
 **YES**      If new information regarding the clinical significance of changes in my WES testing becomes known, I would like Baylor Genetics to issue an updated report which includes this information to my physician who ordered this WES testing.

\_\_\_\_\_  
 **NO**      Please do NOT issue an updated report if there is new information regarding the clinical significance of my WES testing that becomes known.

I hereby authorize Baylor Genetics to conduct genetic testing for myself (or my child) for the Whole Exome Sequencing test as recommended by my physician.

_____ Printed Name	_____ Signature	_____ Date (MM / DD / YYYY)
_____ Relationship to Patient	_____ Proband Name	_____ Proband DOB (MM/DD/YY)
_____ Physician's/Counselor's Signature		_____ Date (MM / DD / YYYY)

### FOR SAMPLES SUBMITTED FROM NEW YORK STATE

INITIAL      I understand that no genetic test other than those I have authorized shall be performed on my biological sample, and the sample will be destroyed at the end of testing or not more than 60 days after the sample was taken. However, by initialing here, I hereby authorize the lab to retain my sample(s) for longer retention in accordance with the laboratory retention policy for internal laboratory quality assurance studies and possible research testing.

\_\_\_\_\_

Consent authorization on next page







## WHOLE EXOME SEQUENCING (WES) PARENTAL CONSENT

\_\_\_\_\_  
Patient Last Name      Patient First Name      MI      Date of Birth (MM / DD / YYYY)      Genetic Sex

### MATERNAL REPORTING OPTIONS AND AUTHORIZATION

INITIAL      1. SECONDARY FINDINGS

Pathogenic and likely pathogenic variants in genes included in the ACMG policy statement regarding recommendations for reporting of incidental findings will be reported as medically actionable on the WES report.

- \_\_\_\_\_  **YES** Please report pathogenic and likely pathogenic variants in genes determined to be medically actionable by the ACMG policy statement.
- \_\_\_\_\_  **NO** Please do NOT report pathogenic or likely pathogenic variants in genes included in the ACMG policy statement.

\_\_\_\_\_  
Mother's Printed Name      Date of Birth (MM / DD / YYYY)      Mother's Signature      Date (MM / DD / YYYY)

### PATERNAL REPORTING OPTIONS AND AUTHORIZATION

INITIAL      1. SECONDARY FINDINGS

Pathogenic and likely pathogenic variants in genes included in the ACMG policy statement regarding recommendations for reporting of incidental findings will be reported as medically actionable on the WES report.

- \_\_\_\_\_  **YES** Please report pathogenic and likely pathogenic variants in genes determined to be medically actionable by the ACMG policy statement.
- \_\_\_\_\_  **NO** Please do NOT report pathogenic or likely pathogenic variants in genes included in the ACMG policy statement.

\_\_\_\_\_  
Father's Printed Name      Date of Birth (MM / DD / YYYY)      Father's Signature      Date (MM / DD / YYYY)

### FOR SAMPLES SUBMITTED FROM NEW YORK STATE

MOTHER'S  
INITIAL

FATHER'S  
INITIAL

**Specimen Retention:** By leaving this section blank, my sample shall be destroyed at the end of the testing process or not more than 60 days after completion of testing. However, by initialing here, I hereby authorize the lab to retain my sample(s) for longer retention in accordance with the laboratory retention policy for internal laboratory quality assurance studies and possible research testing